Next Article in Journal
Synthesis, Characterization, and Application of 1-D Cerium Oxide Nanomaterials: A Review
Next Article in Special Issue
Aberrant Crypt Foci: The Case for Inclusion as a Biomarker for Colon Cancer
Previous Article in Journal
Expression of an Organic Solvent Stable Lipase from Staphylococcus epidermidis AT2
Previous Article in Special Issue
Identification of Tetranectin as a Potential Biomarker for Metastatic Oral Cancer
Int. J. Mol. Sci. 2010, 11(9), 3209-3225; doi:10.3390/ijms11093209

Biomarkers for Colorectal Cancer

1,2,* , 3, 4
1 The Tohkai Cytopathology Institute: Cancer Research and Prevention (TCI-CaRP), 5-1-2 Minami-Uzura, Gifu 500-8285, Japan 2 Department Oncologic Pathology, Kanazawa Medical University, 1-1 daigaku, Uchinada Ishikawa 920-0293, Japan 3 Department of Pharmacy, Kinjo Gakuin University of Pharmacy, Moriyama-Ku, Nagoya, Aichi 463-8521, Japan 4 Department of Physical Therapy, Kansai University of Health Sciences, Kumatori-Machi, Sennan-Gun, Osaka 590-0482, Japan 5 Cancer Prevention Basic Research Project, National Cancer Center Research Institute, Tokyo 104-0045, Japan
* Author to whom correspondence should be addressed.
Received: 18 August 2010 / Revised: 2 September 2010 / Accepted: 3 September 2010 / Published: 13 September 2010
(This article belongs to the Special Issue Biomarkers)
View Full-Text   |   Download PDF [165 KB, uploaded 19 June 2014]


Colorectal cancer (CRC) is the third most common epithelial malignancy in the world. Since CRC develops slowly from removable precancerous lesions, detection of the lesion at an early stage by regular health examinations can reduce the incidence and mortality of this malignancy. Colonoscopy significantly improves the detection rate of CRC, but the examination is expensive and inconvenient. Therefore, we need novel biomarkers that are non-invasive to enable us to detect CRC quite early. A number of validation studies have been conducted to evaluate genetic, epigenetic or protein markers for identification in the stool and/or serum. Currently, the fecal occult blood test is the most widely used method of screening for CRC. However, advances in genomics and proteomics will lead to the discovery of novel non-invasive biomarkers.
Keywords: biomarkers; colorectal cancer; fecal biomarkers; genomic and epigenetic biomarkers; serum biomarkers; microRNA biomarkers; colorectal cancer; fecal biomarkers; genomic and epigenetic biomarkers; serum biomarkers; microRNA
This is an open access article distributed under the Creative Commons Attribution License (CC BY) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
MDPI and ACS Style

Tanaka, T.; Tanaka, M.; Tanaka, T.; Ishigamori, R. Biomarkers for Colorectal Cancer. Int. J. Mol. Sci. 2010, 11, 3209-3225.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here


Cited By

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert